Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation.

@article{Xue2016ComparisonOT,
  title={Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation.},
  author={Zhang Xiao Xue and Wang Xiu Wen and Yu G Zhuang and Zang Jian Hua and Yang Ni Xia},
  journal={Molecular and clinical oncology},
  year={2016},
  volume={5 3},
  pages={265-268}
}
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small-cell lung cancer (NSCLC). Exon 19 deletion and L858R point mutation are the most commonly encountered EGFR mutations in NSCLC, and they predict improved clinical outcomes following treatment with icotinib. The objective of this study was to evaluate the differential clinical efficacy of icotinib in patients with exon 19 deletion or L858R… CONTINUE READING